• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

    2/10/23 9:08:54 AM ET
    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REPH alert in real time by email
    SC 13G/A 1 d9938302_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Societal CDMO, Inc.1
    (Name of Issuer)

     

     

    Common Stock, par value $0.01
    (Title of Class of Securities)

     

     

    75629F109
    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    1 This filing amends the Schedule 13G filed February 8, 2022 for Recro Pharma, Inc.

     
     

     


    CUSIP No.
    75629F109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samjo Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,050,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,050,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,050,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.8%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     
     

     


    CUSIP No.
    75629F109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samjo Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,050,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,050,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,050,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.8%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, OO

     
     
     

     


    CUSIP No.
    75629F109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Andrew N. Wiener  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      64,000  
         
    6. SHARED VOTING POWER  
         
      4,050,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      64,000  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,050,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,114,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      4.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     
     
     

     

    CUSIP No. 75629F109    

     

    Item 1. (a). Name of Issuer:  
           
        Societal CDMO, Inc.  
           
      (b). Address of issuer’s principal executive offices:  
           
       

    1 E. Uwchlan Ave, Suite 112

    Exton, PA 19341

     
           
    Item 2. (a). Name of person filing:  
           
       

    This statement is filed by:

     

     
        (i) Samjo Capital, LLC, a Delaware limited liability company (“Samjo Capital”);
           
        (ii)

    Samjo Management, LLC, a Delaware limited liability company (“Samjo Management”); and

     

        (iii) Andrew N. Wiener, an individual (collectively with Samjo Capital and Samjo Management, the “Reporting Persons”).
           
      (b). Address or principal business office or, if none, residence:  
           
       

    The address of the principal office of the Reporting Persons is:

     

    599 Lexington Avenue, 21st Floor, New York, NY 10022

     

     

     
           
      (c). Citizenship:  
           
       

    Samjo Capital and Samjo Management are Delaware limited liability companies. Mr. Wiener is a U.S. Citizen.

     

     
           
      (d). Title of class of securities:  
           
        Common Stock, par value $0.01  
           
      (e). CUSIP No.:  
           
        75629F109  
               

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:

     

    Not Applicable

     
     

     

    CUSIP No. 75629F109    

     

    Item 4. Ownership.

     

      (a) Amount beneficially owned:
         
       

    Samjo Capital is the beneficial owner of 4,050,000 shares of Common Stock, par value $0.01 (“Common Stock”).

    Samjo Management is the beneficial owner of 4,050,000 shares of Common Stock.

    Andrew N. Wiener is the beneficial owner of 4,114,000 shares of Common Stock.

     

      (b) Percent of class:
         
       

    Samjo Capital beneficially owns 4.8% of the Issuer’s Common Stock.

    Samjo Management beneficially owns 4.8% of the Issuer’s Common Stock.

    Andrew N. Wiener beneficially owns 4.9% of the Issuer’s Common Stock.

     

      (c) Number of shares as to which the person has:
         

     

        (i) Sole power to vote or to direct the vote  
             
          Samjo Capital 0
             
          Samjo Management 0
             
          Andrew N. Wiener 64,000
             

     

        (i) Shared power to vote or to direct the vote  
             
          Samjo Capital 4,050,000
             
          Samjo Management 4,050,000
             
          Andrew N. Wiener 4,050,000
             

     

        (i) Sole power to dispose or to direct the disposition of  
             
          Samjo Capital 0
             
          Samjo Management 0
             
          Andrew N. Wiener 64,000
             

     

     

     
     

     

        (i) Shared power to dispose or to direct the disposition of  
             
          Samjo Capital 4,050,000
             
          Samjo Management 4,050,000
             
          Andrew N. Wiener 4,050,000
             

     

     

     

     

    In addition to his role as the sole Managing Member of Samjo Capital and Samjo Management, Mr. Wiener is also one of the portfolio managers of the CPA Samjo Investment Program ("SI") employed by Cowen Prime Advisors LLC ("CPA"). The clients of Samjo Management and Samjo Capital employ investment strategies that are similar to those employed in the CPA SI program. Samjo Capital, Samjo Management and their clients are not affiliated with CPA and Mr. Wiener does not have beneficial ownership over the shares held in the CPA SI program except for shares held in accounts owned by Mr. Wiener and his immediate family members. As a result, Samjo Capital and Samjo Management do not make joint filings with respect to any shares of the issuer held by any CPA clients except with respect to shares held in accounts owned by Mr. Wiener and his immediate family members. To the best of Samjo Capital's, Samjo Management's and Mr. Wiener's knowledge and belief, CPA reports the ownership of shares by such CPA clients separately to the extent required and is identified as the reporting person.

     

     

    Instruction:  For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).  
       

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  [  ]*.
       
      This final amendment reflects that each reporting person has ceased to be the beneficial owner of more than five percent of the Common Stock of the issuer.
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      All securities reported in this Schedule 13G are owned by advisory clients of Samjo Capital and/or its related persons' proprietary accounts. None of the advisory clients and/or related persons' proprietary accounts individually owns more than 5% of the outstanding Common Stock of the Issuer.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    Exhibit: Joint Acquisition Statement.

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      February 10, 2023
      (Date)
       
      SAMJO CAPITAL, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
     

     

    Andrew N. Wiener, Managing Member

      (Name/Title)

     

     

     

      February 10, 2023
      (Date)
       
      SAMJO MANAGEMENT, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
       
      Andrew N. Wiener, Managing Member
      (Name/Title)
       
     

     

     

      February 10, 2023
      (Date)
       
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
      Andrew N. Wiener
      (Name/Title)
       
       
       

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    EXHIBIT

     

     

    JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

     

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

     

      February 10, 2023
      (Date)
       
      SAMJO CAPITAL, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
     

     

    Andrew N. Wiener, Managing Member

      (Name/Title)

     

     

      February 10, 2023
      (Date)
       
      SAMJO MANAGEMENT, LLC
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
       
      Andrew N. Wiener, Managing Member
      (Name/Title)
       
       
      February 10, 2023
      (Date)
       
       
      /s/ Andrew N. Wiener
      (Signature)
       
       
      Andrew N. Wiener, Managing Member
      (Name/Title)

     

     

    Get the next $REPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPH

    DatePrice TargetRatingAnalyst
    10/12/2021Outperform
    William Blair
    More analyst ratings

    $REPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

      With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a r

      3/21/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Fourth Quarter and Year End 2021 Financial Results

      Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2021. "At this time last yea

      3/1/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

      SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company's San Diego facility and final validation and commissioning activities are underway. The company expects that its new automated fill/finish line and lyophilization

      2/23/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Recro Pharma

      William Blair initiated coverage of Recro Pharma with a rating of Outperform

      10/12/21 7:16:48 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Financials

    Live finance-specific insights

    See more
    • Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

      SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 fr

      2/22/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Third Quarter 2021 Financial Results

      Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third q

      11/9/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021

      SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 fro

      11/2/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 3:53:17 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 2:27:06 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Recro Pharma Inc.

      SC 13G - Societal CDMO, Inc. (0001588972) (Subject)

      8/31/23 11:59:02 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Recro Announces Executive Changes

      MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDM

      12/16/20 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lake Ryan David covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 0.13% to 800,557 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      2/6/24 5:31:29 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enloe J David Jr was granted 196,474 shares, increasing direct ownership by 18% to 1,295,414 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 6:00:30 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 5:59:39 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    SEC Filings

    See more
    • Recro Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/28/23 4:14:11 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Recro Pharma Inc.

      10-Q - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:13:18 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:11:37 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care